- Home
- DMAC vs DOUG Comparison
DMAC vs DOUG Comparison
Compare DMAC & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- DOUG
- Stock Information
- Founded
- DMAC 2000
- DOUG 1911
- Country
- DMAC United States
- DOUG United States
- Employees
- DMAC N/A
- DOUG N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- DOUG Building operators
- Sector
- DMAC Health Care
- DOUG Real Estate
- Exchange
- DMAC Nasdaq
- DOUG Nasdaq
- Market Cap
- DMAC 172.7M
- DOUG 146.0M
- IPO Year
- DMAC N/A
- DOUG N/A
- Fundamental
- Price
- DMAC $4.18
- DOUG $2.50
- Analyst Decision
- DMAC Strong Buy
- DOUG
- Analyst Count
- DMAC 3
- DOUG 0
- Target Price
- DMAC $7.00
- DOUG N/A
- AVG Volume (30 Days)
- DMAC 46.2K
- DOUG 877.2K
- Earning Date
- DMAC 11-13-2024
- DOUG 11-07-2024
- Dividend Yield
- DMAC N/A
- DOUG N/A
- EPS Growth
- DMAC N/A
- DOUG N/A
- EPS
- DMAC N/A
- DOUG N/A
- Revenue
- DMAC N/A
- DOUG $966,442,000.00
- Revenue This Year
- DMAC N/A
- DOUG $4.18
- Revenue Next Year
- DMAC N/A
- DOUG $28.68
- P/E Ratio
- DMAC N/A
- DOUG N/A
- Revenue Growth
- DMAC N/A
- DOUG 1.86
- 52 Week Low
- DMAC $2.14
- DOUG $1.00
- 52 Week High
- DMAC $4.95
- DOUG $3.16
- Technical
- Relative Strength Index (RSI)
- DMAC 48.23
- DOUG 73.84
- Support Level
- DMAC $3.96
- DOUG $1.76
- Resistance Level
- DMAC $4.21
- DOUG $2.23
- Average True Range (ATR)
- DMAC 0.18
- DOUG 0.19
- MACD
- DMAC -0.02
- DOUG 0.05
- Stochastic Oscillator
- DMAC 50.00
- DOUG 90.74
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.